In This Article:
As the U.S. market experiences a notable upswing, with the S&P 500 and Nasdaq Composite marking gains amid strong earnings reports from major tech companies like Microsoft and Meta, investors are keenly observing how these developments impact high-growth tech stocks. In this environment of robust AI spending and positive sentiment, identifying companies with solid financials and innovative strategies becomes crucial for those looking to tap into the potential of high-growth sectors.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 20.35% | 33.99% | ★★★★★★ |
Travere Therapeutics | 28.65% | 66.06% | ★★★★★★ |
TG Therapeutics | 26.06% | 37.39% | ★★★★★★ |
Arcutis Biotherapeutics | 26.11% | 58.46% | ★★★★★★ |
Clene | 62.08% | 64.01% | ★★★★★★ |
Alnylam Pharmaceuticals | 23.08% | 58.85% | ★★★★★★ |
AVITA Medical | 27.81% | 55.17% | ★★★★★★ |
Alkami Technology | 20.71% | 92.32% | ★★★★★★ |
Ascendis Pharma | 32.75% | 59.64% | ★★★★★★ |
Lumentum Holdings | 21.34% | 120.49% | ★★★★★★ |
Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Ardelyx
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ardelyx, Inc. focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market cap of $1.30 billion.
Operations: Ardelyx generates revenue primarily through the development and commercialization of biopharmaceutical products, totaling $333.62 million.
Ardelyx's recent appointment of Dr. Merdad Parsey to its Board underscores a strategic enhancement in governance, potentially enriching its leadership amidst crucial clinical advancements. The company's innovative focus is exemplified by XPHOZAH®, a pioneering treatment for hyperphosphatemia in CKD patients on dialysis, reflecting Ardelyx's commitment to addressing unmet medical needs through novel therapeutic approaches. Financially, Ardelyx has shown significant traction with a revenue jump to $333.62 million from the previous year’s $124.46 million, alongside an anticipated transition to profitability within three years, suggesting robust growth prospects driven by both clinical outcomes and market expansion strategies.
-
Unlock comprehensive insights into our analysis of Ardelyx stock in this health report.
-
Review our historical performance report to gain insights into Ardelyx's's past performance.
Apellis Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutic compounds for diseases with significant unmet needs, with a market cap of approximately $2.41 billion.